Iterum Therapeutics Plc Tops Q3 EPS by 47c
- ByInvesting.com-
Iterum Therapeutics Plc (ITRM) reported Q3 EPS of ($0.43), $0.47 better than the analyst estimate of ($0.90).
Symbol | Exchange | Currency |
---|
Iterum Therapeutics Plc (ITRM) reported Q3 EPS of ($0.43), $0.47 better than the analyst estimate of ($0.90).
Iterum Therapeutics Plc (NASDAQ:ITRM) reported Q2 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06).
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Technology, Consumer Services and Healthcare sectors led shares higher. At the close in NYSE,...
Shares of Iterum Therapeutics plc (NASDAQ:ITRM) crashed 35.7% on Dec 11, following the announcement of disappointing data from a phase III study evaluating its antibiotic...
As of late, it has definitely been a great time to be an investor in Iterum Therapeutics PLC (NASDAQ:ITRM) . The stock has moved higher by 10% in the past month, while it is...
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to improve the lives of people affected by serious and life-threatening diseases around the world. The Company is focused on developing and commercializing sulopenem, which is an oral and intravenous penem. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It is also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes, such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms, including methicillin-susceptible staphylococci, and others.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Neutral | Buy | Strong Buy | Buy | Sell |
Technical Indicators | Buy | Buy | Strong Buy | Strong Buy | Strong Sell |
Summary | Neutral | Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
154.50 | 157.38 | 147.83 | +3.68 | +2.44% | 153.13M | NASDAQ | |||
186.53 | 196.77 | 182.89 | -2.24 | -1.19% | 76.54M | NASDAQ | |||
104.78 | 107.81 | 102.58 | -2.96 | -2.75% | 64.92M | NASDAQ | |||
44.06 | 44.39 | 43.88 | -0.28 | -0.63% | 23.71M | NYSE | |||
164.61 | 166.34 | 163.89 | -0.93 | -0.56% | 6.84M | NYSE | |||
514.80 | 521.55 | 512.50 | -8.63 | -1.65% | 1.83M | NASDAQ | |||
189.98 | 199.00 | 183.69 | +1.71 | +0.91% | 230.29M | NASDAQ | |||
258.35 | 264.20 | 257.10 | -6.26 | -2.36% | 28.73M | NASDAQ | |||
103.39 | 108.78 | 102.52 | -9.52 | -8.43% | 143.31M | NASDAQ | |||
11.19 | 11.90 | 11.16 | -0.77 | -6.44% | 55.80M | NYSE | |||
19.90 | 21.32 | 19.75 | -0.98 | -4.69% | 27.18M | NASDAQ | |||
59.83 | 60.42 | 59.23 | -0.45 | -0.75% | 15.38M | NYSE | |||
369.95 | 374.57 | 365.44 | +0.48 | +0.13% | 2.22M | NYSE | |||
141.09 | 142.33 | 138.13 | +2.15 | +1.55% | 11.48M | NYSE | |||
264.23 | 265.22 | 261.35 | +1.02 | +0.39% | 3.00M | NYSE |